Bronchiectasis Care in Focus: Pathophysiology, Diagnosis, and Reducing Mortality

A first-in-class neutrophil-targeted therapy has given clinicians a new tool against bronchiectasis, but Dr. Sala says key populations, including the immunocompromised, still lack answers.

With more therapies now available, Dr. Sala walks through how he layers DPP1 inhibition alongside existing treatments, and the one group that needs it most urgently.

Payer access to a new bronchiectasis therapy has mostly gone smoothly, but Dr. Sala describes pushing back against outdated prior-therapy requirements that trials never required.

Bronchiectasis isn't reversible, so Dr. Sala focuses on coaching patients toward a sustainable relationship with chronic cough rather than chasing a cure that doesn't exist.

From eosinophil-targeted biologics to a cardiology-style risk calculator, Dr. Sala outlines the innovations that could finally make bronchiectasis prevention, not just treatment, possible.

Bronchiectasis pathophysiology looks less linear and more dynamic than once believed, and its true prevalence appears far higher than commonly assumed across the adult population.

Behind every case of bronchiectasis is a self-perpetuating cycle of cough, breathlessness, and infection that leaves many patients unable to return to their prior baseline health.